Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Background: We investigated outcomes with cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC) with or without prior nephrectomy in the phase 3 METEOR trial (NCT01865747). Methods: Patients (N = 658) with advanced clear cell RCC and prior treatment with≥1 VEGFR tyrosin...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Nizar M. Tannir, Thomas Powles, Bernard Escudier, Frede Donskov, Viktor Grünwald, Cora N. Sternberg, Manuela Schmidinger, Patrick Schöffski, Cezary Szczylik, Katriina Peltolta, Dmitry Nosov, Bohuslav Melichar, Douglas Clary, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri
Format:	Artigo
Jezik:	Inglês
Izdano:	SAGE Publishing 2020-03-01
Serija:	Kidney Cancer
Online dostop:	https://doi.org/10.3233/KCA-190080
Oznake:	Označite Brez oznak, prvi označite!